We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum–Etoposide Chemotherapy.
- Authors
Morimoto, Kenji; Yamada, Tadaaki; Takeda, Takayuki; Shiotsu, Shinsuke; Date, Koji; Harada, Taishi; Tamiya, Nobuyo; Chihara, Yusuke; Takemura, Yoshizumi; Yamada, Takahiro; Kanda, Hibiki; Ishida, Masaki; Yoshimura, Akihiro; Iwasaku, Masahiro; Tokuda, Shinsaku; Kim, Young Hak; Takayama, Koichi
- Abstract
Background: Programmed death-ligand 1 (PD-L1) inhibitor plus platinum–etoposide chemotherapy is used as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), regardless of age. Objective: We examined the role of the Geriatric 8 (G8) screening tool for evaluating treatment outcomes in patients with ES-SCLC treated with PD-L1 inhibitor plus platinum–etoposide chemotherapy as first-line therapy. Patients and Methods: Between September 2019 and October 2021, we prospectively evaluated patients with ES-SCLC treated with immunochemotherapy at ten institutions in Japan. The G8 score was assessed before treatment initiation. Results: We evaluated 44 patients with ES-SCLC. Patients with G8 score > 11 had longer overall survival (OS) than those with G8 score ≤ 11 (not reached versus 8.3 months; log-rank test, p = 0.005). In univariate and multivariate analyses, G8 score > 11 [hazard ratio (HR) 0.34; 95% confidence interval (CI) 0.15–0.75; p = 0.008 and HR 0.34; 95% CI 0.14–0.82; p = 0.02, respectively) and performance status (PS) of 2 (HR 5.42; 95% CI 2.08–14.2; p < 0.001 and HR 6.94; 95% CI 2.25–21.4; p < 0.001, respectively) were independent prognostic factors for OS. Among patients with good PS (0 or 1), the OS in patients with G8 score > 11 was significantly longer than that in patients with G8 score ≤ 11 (not reached versus 12.3 months; log-rank test, p = 0.02). Conclusions: G8 score evaluation before treatment initiation was useful as a prognostic factor for ES-SCLC patients who received PD-L1 inhibitors and platinum–etoposide chemotherapy, even with good PS.
- Subjects
JAPAN; THERAPEUTIC use of antineoplastic agents; LUNG cancer; ETOPOSIDE; CANCER patient psychology; STATISTICS; PROGRAMMED death-ligand 1; SCIENTIFIC observation; CONFIDENCE intervals; LOG-rank test; MULTIVARIATE analysis; LUNG tumors; GERIATRIC assessment; EARLY detection of cancer; PLATINUM; TREATMENT effectiveness; LONGITUDINAL method; OVERALL survival; EVALUATION
- Publication
Drugs & Aging, 2023, Vol 40, Issue 6, p563
- ISSN
1170-229X
- Publication type
Article
- DOI
10.1007/s40266-023-01034-4